We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Keith Blundy.
- Authors
Blundy, Keith; Mullard, Asher
- Abstract
The non-profit Cancer Research UK (CRUK) funds over £300 million worth of cancer research each year and, with the help of its development and commercialization arm Cancer Research Technology (CRT), has moved more than 30 partnered agents into preclinical and clinical development. Having established a small-molecule track record, CRUK now needs to build up more biologic know-how, says CRT Chief Executive Officer Keith Blundy. To this end, CRUK and AstraZeneca's antibody subsidiary, MedImmune, agreed in September to launch the joint CRUK-MEDI Alliance Laboratory. This fully collaborative and integrated partnership is a first of its kind, Blundy tells Asher Mullard.
- Publication
Nature Reviews Drug Discovery, 2014, Vol 13, Issue 11, p806
- ISSN
1474-1776
- Publication type
interview
- DOI
10.1038/nrd4480